ICI-170809
Chemical compound
ICI-170809 is a chemical compound that acts as a selective 5-HT4 receptor agonist. It was developed for its potential therapeutic effects on cognitive disorders and gastrointestinal motility disorders.
Chemical Properties[edit]
ICI-170809 is a synthetic compound with a complex chemical structure. It is characterized by its ability to selectively bind to and activate the 5-HT4 receptor, a subtype of the serotonin receptor family. This receptor is primarily found in the central nervous system and the gastrointestinal tract.
Pharmacology[edit]
ICI-170809 functions as a potent agonist at the 5-HT4 receptor. Activation of this receptor is known to enhance the release of acetylcholine in the brain, which is associated with improved cognitive function. This makes ICI-170809 a compound of interest in the study of neurodegenerative diseases such as Alzheimer's disease.
In the gastrointestinal system, 5-HT4 receptor activation by ICI-170809 can lead to increased gastrointestinal motility, making it a potential treatment for conditions like irritable bowel syndrome and chronic constipation.
Research and Development[edit]
Research into ICI-170809 has primarily focused on its effects on cognitive enhancement and gastrointestinal motility. Preclinical studies have shown promising results in animal models, where the compound improved memory and learning capabilities. However, further research is needed to fully understand its efficacy and safety in humans.
Potential Therapeutic Uses[edit]
ICI-170809 has been investigated for several potential therapeutic applications:
- Cognitive Disorders: Due to its action on the 5-HT4 receptor, ICI-170809 may help in the treatment of cognitive impairments associated with neurodegenerative diseases.
- Gastrointestinal Disorders: Its ability to enhance gastrointestinal motility suggests potential use in treating conditions like irritable bowel syndrome and chronic constipation.
Safety and Side Effects[edit]
As with any pharmacological agent, the safety profile of ICI-170809 is a critical aspect of its development. While preclinical studies have not shown significant adverse effects, comprehensive clinical trials are necessary to establish its safety in humans.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
